drug · gene
lovotibeglogene autotemcel
Phase 3updated 6mo agoby Genetix Biotherapeutics Inc🔗 ChEMBL
Phase 3community read0 votes
Gene drug with a maximum clinical stage of Approval, with an approval for sickle cell disease.
indications
indications
Sickle Cell Disease
targets
Hemoglobin subunit beta
all catalysts(0)
nothing on the calendar yet
News(7)
- Genetix’s genetic medicines are officially profitable, with $327M in sales YTDIt’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech…biospace · 2d ago
- Marrow Therapeutics debuts with $173M to tackle blood disorders in vivoMarrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.biospace · 2d ago
- Marrow sets out to challenge genetic medicines for severe blood diseasesArmed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta tha…biopharma_dive · 2d ago
- Marrow extracts $120M series B to advance preclinical blood disease therapyA new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…fiercebiotech · 6d ago
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 8d ago
- Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdownGearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…fiercebiotech · 8d ago
- New FDA draft guidance doubles down on expediting approvals of personalized gene therapiesThe FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same time, the Centers for Medicare & Medicaid Services has revealed plans to e…biospace · 21d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that